CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium.

被引：0
|
作者：
Margolin, KA
Longmate, J
Baratta, T
Synold, T
Weber, J
Gajewski, T
Quirt, I
Christensen, S
Doroshow, JH
机构：
[1] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA
[2] Univ Chicago, Sch Med, Chicago, IL 60637 USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页码：715S / 715S
页数：1
相关论文
共 50 条
  • [21] Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.
    Farag, S. S.
    Zhang, S.
    Miller, M.
    Buckner, M.
    Kraut, E.
    Chan, K.
    Eng, C.
    Byrd, J. C.
    Dancey, J. E.
    Grever, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
  • [22] Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
    Peralba, JM
    DeGraffenried, L
    Friedrichs, W
    Fulcher, L
    Grünwald, V
    Weiss, G
    Hidalgo, M
    CLINICAL CANCER RESEARCH, 2003, 9 (08) : 2887 - 2892
  • [23] Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
    Hofmeister, Craig C.
    Yang, Xiaoxia
    Pichiorri, Flavia
    Chen, Ping
    Rozewski, Darlene M.
    Johnson, Amy J.
    Lee, Seungsoo
    Liu, Zhongfa
    Garr, Celia L.
    Hade, Erinn M.
    Ji, Jia
    Schaaf, Larry J.
    Benson, Don M., Jr.
    Kraut, Eric H.
    Hicks, William J.
    Chan, Kenneth K.
    Chen, Ching-Shih
    Farag, Sherif S.
    Grever, Michael R.
    Byrd, John C.
    Phelps, Mitch A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3427 - 3434
  • [24] G3139 plus α-interferon (IFN) in metastatic renal cancer (RCC):: A phase II study of the California Cancer Consortium.
    Margolin, KA
    Lara, P
    Quinn, D
    Dutcher, J
    Frankel, P
    Doroshow, J
    Gandara, D
    Synold, T
    Lacey, SF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 426S - 426S
  • [25] Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: Preliminary results
    Baselga, J
    Fumoleau, P
    Gil, M
    Colomer, R
    Roche, H
    Cortes-Funes, H
    Burstein, H
    Kaufman, P
    Kong, S
    Moore, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 13S - 13S
  • [26] Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium.
    Sridhar, SS
    Stadler, W
    Le, L
    Hedley, D
    Pond, G
    Wright, J
    Vokes, E
    Thomas, S
    Moore, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 422S - 422S
  • [27] Phase I and pharmacological study of CCI-779, a cell cycle inhibitor.
    Hidalgo, M
    Rowinsky, E
    Erlichman, C
    Drengler, R
    Marshall, B
    Adjei, A
    Hammond, L
    Galanis, E
    Edwards, T
    Burton, J
    Boni, J
    Tolcher, A
    Dukart, G
    Buckner, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4548S - 4549S
  • [28] Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.
    Ghobrial, Irene M.
    Munshi, Nikhil
    Schlossman, Robert
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    Sam, Amy
    O'Connor, Kelly
    Harris, Brianna
    Warren, Diane
    Dollard, Akari M.
    Laubach, Jacob
    Vij, Ravi
    Campagnaro, Erica
    Birner, Ann
    Dixon-Lipscomb, Virginia
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2008, 112 (11) : 1266 - 1266
  • [29] A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
    Li, Tianhong
    Christensen, Scott D.
    Frankel, Paul H.
    Margolin, Kim A.
    Agarwala, Sanjiv S.
    Luu, Thehang
    Mack, Philip C.
    Lara, Primo N., Jr.
    Gandara, David R.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 741 - 748
  • [30] A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial
    Tianhong Li
    Scott D. Christensen
    Paul H. Frankel
    Kim A. Margolin
    Sanjiv S. Agarwala
    Thehang Luu
    Philip C. Mack
    Primo N. Lara
    David R. Gandara
    Investigational New Drugs, 2012, 30 : 741 - 748
12345